Virtus Lifesci Biotech Etf Profile
| BBC Etf | USD 26.85 0.73 2.79% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Virtus LifeSci is trading at 26.85 as of the 23rd of November 2024, a 2.79 percent increase since the beginning of the trading day. The etf's open price was 26.12. Virtus LifeSci has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Virtus LifeSci Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of August 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Under normal market conditions, the fund will invest not less than 80 percent of its assets in component securities of the index. Virtus Lifesci is traded on NYSEARCA Exchange in the United States. More on Virtus LifeSci Biotech
Moving together with Virtus Etf
Moving against Virtus Etf
Virtus Etf Highlights
| Thematic Ideas | (View all Themes) |
| Business Concentration | Sector ETFs, Health Care ETFs, Health, Virtus (View all Sectors) |
| Issuer | Virtus |
| Inception Date | 2014-12-16 |
| Benchmark | LifeSci Biotechnology Clinical Trials Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 10.42 Million |
| Average Trading Valume | 1,847 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | Virtus ETF Solutions, LLC |
| Advisor | Virtus ETF Advisers LLC |
| Custodian | The Bank of New York Mellon Corporation |
| Distributor | ETF Distributors LLC |
| Portfolio Manager | Matthew B. Brown, Seth Kadushin |
| Transfer Agent | The Bank of New York Mellon Corporation |
| Fiscal Year End | 31-Oct |
| Exchange | NYSE Arca, Inc. |
| Number of Constituents | 123 |
| Market Maker | Virtu Financial |
| Total Expense | 0.79 |
| Management Fee | 0.79 |
| Country Name | USA |
| Returns Y T D | 7.01 |
| Name | Virtus LifeSci Biotech Clinical Trials ETF |
| Currency Code | USD |
| Open Figi | BBG007QVCGG1 |
| In Threey Volatility | 35.62 |
| 1y Volatility | 36.47 |
| 200 Day M A | 27.8008 |
| 50 Day M A | 28.7384 |
| Code | BBC |
| Updated At | 22nd of November 2024 |
| Currency Name | US Dollar |
Virtus LifeSci Biotech [BBC] is traded in USA and was established 2014-12-16. The fund is classified under Health category within Virtus family. The entity is thematically classified as Sector ETFs. Virtus LifeSci Biotech currently have 18.12 M in assets under management (AUM). , while the total return for the last 3 years was -15.2%.
Check Virtus LifeSci Probability Of Bankruptcy
Geographic Allocation (%)
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Virtus Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Virtus Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as Virtus LifeSci Biotech Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Top Virtus LifeSci Biotech Etf Constituents
| PBYI | Puma Biotechnology | Stock | Health Care | |
| KRTX | Karuna Therapeutics | Stock | Health Care | |
| CBAY | Cymabay Therapeu | Stock | Health Care | |
| ITCI | Intracellular Th | Stock | Health Care | |
| FOLD | Amicus Therapeutics | Stock | Health Care | |
| DVAX | Dynavax Technologies | Stock | Health Care | |
| DCPH | Deciphera Pharmaceuticals LLC | Stock | Health Care | |
| KNSA | Kiniksa Pharmaceuticals | Stock | Health Care |
Virtus LifeSci Biotech Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Virtus LifeSci. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.06) |
Virtus LifeSci Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Virtus LifeSci Biotech. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
The market value of Virtus LifeSci Biotech is measured differently than its book value, which is the value of Virtus that is recorded on the company's balance sheet. Investors also form their own opinion of Virtus LifeSci's value that differs from its market value or its book value, called intrinsic value, which is Virtus LifeSci's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Virtus LifeSci's market value can be influenced by many factors that don't directly affect Virtus LifeSci's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Virtus LifeSci's value and its price as these two are different measures arrived at by different means. Investors typically determine if Virtus LifeSci is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Virtus LifeSci's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.